DUBLIN, Ireland and PRAGUE, Czech Republic, May 11 /PRNewswire-FirstCall/
-- Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"), (AIM:
AP.L), the healthcare technology company focussed on the consumer woundcare,
oral care and coronary health markets, today announces the signing of a
technology and product development agreement with nanofibre technology
specialists ELMARCO s.r.o. ("Elmarco") of the Czech Republic for the
development of a next generation delivery platform for Alltracel's m-doc(TM)
Elmarco (www.elmarco.cz/en_profil.php) is a specialist R&D and
manufacturing company specialising in advanced manufacturing for the
semi-conductor components industry as well as equipment for industrial
production of nanofibrous non-woven materials.
Together with the Textiles Faculty of the Technical University of
Liberic, Elmarco have developed a novel, proprietary & patented process for
spinning polymers into nano-scale fibres for a range of industrial, chemical,
micro-electronic and bio-medical applications.
Over the past few months m-doc(TM) based nanofibre woundcare prototypes
have been developed and are now at an advanced stage of technical evaluation.
Alltracel's CEO Tony Richardson commented, "Alltracel has always been
committed to innovation in our markets and we are particularly excited by the
prospects for m-doc(TM) based nanofibrous advanced woundcare delivery systems.
Although at an early stage of development nanofibre technology is showing
market transforming potential in a number of our markets and we are delighted
to have formalised our partnership with Elmarco and the nanofibre technology
team at the Technical University of Liberic.
We are now focussed on jointly reviewing a range of patent protected
potential applications for m-doc(TM) based nanofibre solutions, initially for
the advanced woundcare and surgical markets and bringing these innovations to
market via our network of existing and new commercial partners."
Notes to Editors
Alltracel (AIM: AP.L) (www.alltracel.com) Alltracel Pharmaceuticals Plc
is a Healthcare Technology Company focussed on the Consumer Woundcare,
Oral-Care and Coronary Health markets.
With corporate headquarters in Dublin, Ireland; Alltracel has a
commercial office in London, England; R&D subsidiary in the Czech Republic
and manufacturing facilities in Shenzhen, China.
Alltracel was founded in 1996 and listed on London's Alternative
Investment Market in July 2001.
m-doc(TM) (Micro Dispersed Oxidized Cellulose; (www.m-doc.com)) is the
end product of Alltracel's patented process and is currently targeting two
- In the Consumer HealthCare market this process applied to cotton in the
form of raw cellulose is proven as an effective and efficient haemostatic
(blood-stopping) agent. Here m-doc(TM) is currently being marketed as the
leading stops bleeding ingredient brand within recognized wound care, oral
care and relevant first aid brands worldwide.
- In the Coronary Health market, EU based pre-clinical and patient
studies have demonstrated the m-doc(TM) technology platform success in
lowering cholesterol and have indicated longer term coronary health benefits.
In addition pre-clinical work showed significant indications that the
m-doc(TM) coronary health benefits are additive in nature, to both statins
and sterols. Further efficacy, dosage and timing/phasing studies to determine
optimum delivery systems, formats and combinations in both the nutraceutical
and pharmaceutical markets are underway. Development discussions with
potential partners in the nutraceutical and pharmaceutical sectors in both
the EU and North America have commenced.
blotters(TM) is Alltracel's branded blood stopping thin film technology
for the consumer first aid and grooming markets. The blotters(TM) are small,
thin, film strips (similar to breath freshener strips) impregnated with
m-doc(TM) - Alltracel's unique blood stopping ingredient and are packed in a
convenient pocket-sized plastic dispenser. When placed on minor cuts e.g.
shaving nicks m-doc(TM) is released on contact with the blood, forming a soft
gel-like layer over the wound to stop the bleeding fast.
SEAL-ON(TM) (www.seal-on.com ) is the world's first first-aid treatment
brand featuring stops bleeding m-doc(TM) as standard. The SEAL-ON(TM) range
features seven different product delivery systems - sprays, nasal plugs,
patches, powder, plasters, dressings and blotters(TM) -- each designed for
specific usage occasions and all containing the stops-bleeding m-doc(TM)
m-doc(TM), blotters(TM), SEAL-ON(TM) are all trademarks of Alltracel
For further information contact:
Dublin: Denise Cronin
London: Deborah Scott/Davina Langdale
Financial Dynamics: +44-207-831-3113
New York: Sean Leous
Financial Dynamics: +1-212-850-5626
SOURCE Alltracel Pharmaceuticals Plc